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Abstract
Understanding the pharmacokinetics of drugs in peripheral body compartments, such as the genital
tract, is particularly important in the infectious diseases arena. However, extracting drugs from small
volumes of viscous, proteinacious substances like cervicovaginal fluid is particularly challenging.
The goal of this study was to develop a method to quantify raltegravir, an HIV-1 integrase inhibitor,
in the female genital tract. The method included sample preparation with perchloric acid followed
by solid-phase extraction, separation with reverse-phase high-performance liquid chromatography,
and detection with an ultraviolet wavelength of 218 nm. The method was linear from 0.05 to 10.0
mg/L, with minimal endogenous interference. The method was accurate (1.2–11.0% deviation) and
precise (1.1–12.6% CV) for both within and between-day analyses. The ability to detect raltegravir
in the female genital tract is essential for future investigations of raltegravir as an agent for prevention
of HIV acquisition, and this method will be used for clinical studies further evaluating
pharmacokinetic–pharmacodynamic relationships in this body compartment.
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1. Introduction
The majority of HIV infections result from heterosexual transmission [1]. Therefore, to abate
the HIV epidemic, interventions to prevent the sexual transmission of HIV are needed. Pre-
and post-exposure prophylaxis of HIV transmission using oral antiretroviral (ARV) drugs is a
potential approach to prevention [2]. Raltegravir, a novel HIV integrase inhibitor, holds
promise as an HIV prophylactic agent due to its mechanism of action and its effectiveness in
HIV treatment [3]. However, the effectiveness of raltegravir for this purpose may rely on its
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ability to accumulate in female genital tract (FGT) secretions. Therefore, in order to be
considered for further study in pre- and post-exposure prophylaxis against HIV infection, the
pharmacokinetics of raltegravir in female genital tract secretions must be understood.
Currently, two approaches have been published to collect FGT fluid for detection of ARVs:
pelvic lavage [4] and direct aspiration [5]. Although a much simpler analytical approach can
be used with lavage fluid, the extent to which secretions are diluted can only be estimated, and
hence this collection strategy is only semi-quantitative at best. Since lavage can result in
potentially misleading results in pharmacokinetic and pharmacodynamic studies, in which
accurate measures of drug concentration are crucial [4,5], the goal of this study was to develop
an analytical method to measure raltegravir in direct aspirates of CVF using a previously
validated solid-phase extraction (SPE) and high-performance liquid chromatography (HPLC)
method for measuring raltegravir in plasma [6].
2. Materials and methods
2.1. Chemicals and solvents
Raltegravir monopotassium salt was obtained from Merck Research Laboratories (Rahway,
NJ, USA). Diazepam, used as the internal standard, was purchased from Sigma Chemical
Company (St. Louis, MO, USA). HPLC-grade solvents (water, methanol, and acetonitrile),
ammonium acetate, trifluoroacetic acid (TFA), perchloric acid (PCA), glacial acetic acid, and
tetrabutylammonium phosphate (TBAP) were purchased from Fisher Scientific (Norcross, GA,
USA). Human free drug CVF was pooled from healthy donors at the University of North
Carolina at Chapel Hill. Purified compressed nitrogen gas was obtained from National Welders
Supply (Charlotte, NC, USA).
2.2. Equipment
A high-performance liquid chromatography (HPLC) system consisting of an Agilent
Technologies (Wilmington, DE, USA) Model HP1100 binary pump, an HP1100 degasser, and
HP1100 auto sampler, and Agilent 1100 UV-DAD-detector, and HP ChemStation software
(Version A.10.03) on an IBM computer (operated by Windows XP professional), was used for
this method. A Waters Symmetry® C18, 3.5 µm, 3.0 mm × 150 mm analytical column was
used with a Waters Symmetry® C18, 5.0 µm, 3.9mm × 20mm guard column. An Eppendorf
5415D centrifuge (Hamberg, Germany) and Turbovap LV evaporator from Zymark
(Hopkinton, MA, USA) were used in sample processing.
2.3. Preparation of standards
A clear stock solution of raltegravir was prepared at a concentration of 1mg/mL using 5.46 mg
of raltegravir potassium dry base powder (molecular weight 482.51 g) dissolved in 5.0 mL
HPLC-grade water. The master stock solution was prepared by diluting 1.0 mL of the stock
solution with 9.0 mL of HPLC-grade water to a final concentration of 100 µg/mL. This 100
µg/mL master stock solution was added to drug-free pooled human CVF diluted 1:3 with
normal saline to give final working concentrations of 0.05, 0.1, 0.5, 1.0, 5.0, and 10.0 µg/mL.
Quality control (QC) samples at a final concentration of 0.06, 0.6 and 6.0 µg/mL were also
prepared using a 1:3 dilution of CVF. A 1:3 dilution of CVF was used to create the calibrators
to ensure accurate pipetting of the viscous, mucous matrix, and homogenous dispersion of
raltegravir within the matrix. To obtain drug-free pooled CVF, samples from healthy volunteers
were obtained from the posterior fornix of the vagina via direct aspiration with a volumetric
vaginal aspirator. The University of North Carolina (UNC) institutional review board approved
the sample collection protocol and all subjects provided written informed consent before any
collection procedures were performed.
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2.4. Internal standard (IS) preparation
Diazepam (10 mg) was dissolved in a 50:50 solution of methanol and water to achieve a final
concentration of 1 mg/mL (stock solution). From this solution, an aliquot was diluted in HPLC-
water to a final concentration of 2 µg/mL (working solution).
2.5. Simulated vaginal fluid (SVF) investigations
Because of the scarcity of the CVF matrix, SVF based on the constituents and pH of human
vaginal secretions [7], was tested to determine if it could reasonably substitute as the matrix
for standard curves and QCs. If found to be accurate, precise, and comparable to actual CVF
results with raltegravir, it could be used in place of donor drug-free CVF for calibration curves
and QCs. The SVF consisted of the following ingredients: 1.76 g sodium chloride, 0.7 g
potassium hydroxide, 0.111 g calcium hydroxide, 0.009 g bovine serum albumin, 1.0 g lactic
acid, 0.5 g acetic acid, 0.08 g glycerol, 0.2 g urea, and 2.5 g glucose. This was brought to a
volume of 500 mL with HPLC-grade water. The pH of the resulting solution was 4.2.
2.6. Sample collection and processing
CVF samples were collected from healthy subjects that received an oral dose of raltegravir
enrolled in a pharmacokinetic study. CVF was collected in the same manner as the drug-free
pooled CVF used to make the calibrators. CVF was kept on ice before being stored in pre-
weighed cryovials at −80 °C within 1 h of collection. Before processing, collection tubes were
weighed to determine the weight of CVF collected (mg). To prepare for extraction, 100 µL of
calibrators made in a 1:3 dilution of CVF with normal saline, or 100 µL of undiluted CVF
sample collected in the pharmacokinetic study, were transferred to a 1.5 mL Eppendorf tube
using a positive displacement pipettor. If 100 µL of sample was not collected by the subject
or could not be pipetted due to its viscous nature, a known amount that could be pipetted was
used and the amount recorded. The peak area detected was adjusted for the volume pipetted
compared to the 100 µL standard. If it was not possible to accurately pipette a small volume
of CVF, the perchloric acid and internal standard were added directly to the cryovial. The
cryovial was vortexed so that the entire CVF sample was rinsed into the 1.5 mL Eppendorf
tube. For these samples, the weight of CVF collected was used to estimate the volume of sample
collected (1mg= 1 µL) in order to calculate the sample concentration.
To the 1.5 mL Eppendorf tubes, 200 µL of 1% perchloric acid was added, along with 100 µL
of internal standard working solution (diazepam 2 µg/mL). All tubes containing this mixture
(CVF sample or calibrator + 1%perchloric acid + internal standard) were vortexed twice for
30 s each, and centrifuged at 13,000rpm for 5min. Three different concentrations of perchloric
acid (0%, 1%, and 2.5%) were tested with QC samples to compare extraction efficiency.
2.7. SPE method
Solid-phase extraction Bond Elute® columns (1.0 mL, 100 mg, Varian, Harbor City, CA, USA)
were placed in a vacuum elution manifold (20-SPE system, Waters, Milford, MA, USA). The
cartridges were rinsed with 1.0 mL of methanol, and conditioned with 1.0 mL of 150 mM
ammonium acetate (pH 5.0). The entire volume of supernatant after sample and calibrator
processing was applied directly to the column. The sample mixtures were allowed to pass
through the column bed with reduced pressure (2–4 mmHg). The column was further washed
with 1.0 mL of 5% methanol in 50 mM ammonium acetate buffer (pH 6.7), and the bed was
suctioned dry (>5.0 mmHg) for at least 1min. The analyte and internal standard were then
eluted with 500 µL of 1.5% glacial acetic acid (99.9%) in methanol into a clean 1.5 mL
Eppendorf tube. The eluent was evaporated to dryness (approximately 50–60 min) under a
gentle nitrogen stream at 45 °C, and the residue was reconstituted with 50 µL of mobile phase
(A). The resulting solution was carefully vortex-mixed twice for 30 s each, and centrifuged at
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13,000 rpm for 10 min. The supernatant was transferred to 200 µL HPLC microvials (Agilent
Technologies) and 40 µL injected (dead volume is less than 2 µL) onto the column.
2.8. High-performance liquid chromatographic conditions
Chromatographic separation was achieved using a Symmetry® C18 analytical column (150
mm × 3.0 mm, 3.5 µm particle size, Waters Corp., Milford, MA, USA), with a Symmetry®
C18 guard column (20 mm × 3.9 mm, 5 µm particle size, Waters Corp.). The absorbance was
monitored at 218 nm (λmax). Two mobile phase components were used. Mobile phase A
consisted of 25mMsodium phosphate (monobasic) buffer, 20% acetonitrile, and 0.5mM TBAP
(pH 4.0). Mobile phase B consisted of 19.5% acetonitrile, 80% methanol and 0.5% TFA. The
analysis was performed using a binary linear gradient, transitioning from 70% to 3% (compared
to 73% to 3% in the plasma method [6]) mobile phase A over the initial 11 min of run time,
with 4 additional minutes of re-equilibration to initial conditions. A flow rate gradient was also
employed, transitioning from 0.55 mL/min to 0.60 mL/min (compared to 0.55 to 0.70 mL/min
in the plasma method [6]) over the initial 10 min, and returning to 0.55 mL/min at 15 min. The
analysis was performed at 40 °C.
3. Results
3.1. Simulated vaginal fluid experiment
The standard curve using SVF with raltegravir was linear and resulted in a regression
coefficient (r2) of 0.995. However, unacceptable variability in sample extraction was found
with this matrix. The extraction efficiency ranged from 60% to 109% for the 0.06 mg/L QC
concentration, 66% to 93% for the 0.6 mg/L QC concentration, and 82% to 94% for the 6.0
mg/L QC concentration over three separate days. Average extraction efficiency for these three
concentrations over 3 days ranged from 70% to 99%. Using this matrix, the range of %
accuracies was 65–110% for the standard curve, and 80–127% for the QCs. Due to the
inconsistent results obtained with SVF, development of the method continued with drug-free
CVF obtained from healthy volunteers.
3.2. Linearity, limit of quantification
Because of the mucous, proteinacious nature of CVF, it was difficult to achieve a homogenous
solution of drug and internal standard using undiluted matrix. After evaluating different
dilutions of this matrix, it was determined that a 1:3 dilution of CVF to normal saline provided
for the most accurate pipetting of sample, and this dilution was used to create calibrators for
the method. Peak area RAL:IS ratios for the calibration standards were proportional to the
concentration of raltegravir in plasma over the range tested. The calibration curves were fitted
by linear weighted least-squares regression. The linear regression data for the calibration curves
of the method consistently demonstrated a regression coefficient (r2)≥0.999. The method was
linear from 0.05 to 10.0 mg/L. Linearity was also tested without the internal standard to
determine the direct proportionality of RAL peak areas with their corresponding
concentrations.
3.3. Selectivity and specificity
The approximate retention times for RAL and IS were 6.9 and 9.9 min, respectively. There
was minimal interference from endogenous substances with the analyte or internal standard in
the CVF extracts. Fig. 1a and b illustrates a blank chromatogram of extracted CVF and the
0.06 mg/L QC sample, respectively.
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3.4. Accuracy and precision
Results of the method validation are shown in Table 1. The average concentration calculated
from the standard curve for all QCs at the 0.06, 0.6, and 6mg/L levels were .068, 0.61, and
6.54 mg/L, respectively. All observed data (within-day and between-day accuracy [%
deviation] and precision [%CV]) were below 15%. The accuracy of RAL, represented as
percent deviation from the nominal concentration, ranged from 1.2% to 11.0% for all three
concentrations for both within-day and between-day analysis. The method’s precision for RAL
ranged from 1.1% to 12.6% for both within-day and between-day analysis.
3.5. Extraction efficiency (recovery %)
The recovery of raltegravir after solid-phase extraction was determined by comparing the
average observed peak area of extracted QCs in triplicate, to that of an expected peak area for
each QC calculated from a solution of 10 µg/mL raltegravir in mobile phase A. Three sample
preparation methods were compared to determine the amount of protein precipitation required:
HPLC-grade H2O (0% perchloric acid), 1% perchloric acid, or 2.5% perchloric acid. Table 2
gives the percentage recovery for the three sample preparation techniques at the QC
concentrations. When only water was added to the sample preparation, the 0.06 mg/L
concentration did not have a detectable peak above baseline. In the higher concentrations, 0.6
and 6.0 mg/L, it was evident in the chromatogram that there was endogenous interference
present in the matrix. When added in a concentration of 2.5%, the perchloric acid decreased
the amount of endogenous interference. However, no peak was detected at 0.06 mg/L,
suggesting that the altered pH of the sample adversely affected the extraction of raltegravir in
the solid-phase packing. Therefore, the concentration of perchloric acid was decreased to 1%,
and was found to have the best extraction efficiency with the least amount of interference.
3.6. Method application
This method was used to quantify raltegravir in 166 CVF samples from 7 subjects enrolled in
a pharmacokinetic study; the data for which has been recently presented [8]. The University
of North Carolina (UNC) institutional review board approved all sample collections under
study protocol and all subjects provided written informed consent before any study procedures
were performed. Fig. 1c shows the analysis of one of these samples. Fig. 2 represents a mean
(SE) pharmacokinetic concentration versus time profile of raltegravir in the CVF and blood
plasma of 3 healthy volunteers. Subjects received raltegravir 400 mg twice daily for 7 days.
Samples were collected immediately following the last dose on day 7.
4. Discussion
This is the first method to quantify the novel integrase inhibitor raltegravir in cervicovaginal
fluid. Only two methods have been published for measuring antiretroviral drug concentrations
in CVF: pelvic lavage [4] and direct aspiration [5]. A lavage method can be semi-quantitative
if a marker exists to estimate the amount of dilution. To our knowledge, no one has been able
to identify a marker to accurately correct for the dilution factor in pelvic lavage. However, the
direct aspiration method has been successfully used for quantifying nucleoside reverse
transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, and
CCR5 receptor antagonists [9].
To pursue development of an assay for measuring raltegravir in directly aspirated CVF, we
chose to modify our previously published method for measuring raltegravir in blood plasma
[6]. In the plasma method, blood samples were collected from subjects in sodium EDTA tubes
and centrifuged at 2800 rpm for 15 min at 4 °C. Plasma was transferred to clean cryovials and
stored at−70 °C. Prior to extraction, all patient plasma samples were heated for 60 min at 58 °
C to inactivate the HIV virus. Samples were brought to room temperature and applied directly
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to Bond Elute® columns for SPE. No further sample preparation was required prior to SPE. A
binary linear mobile phase gradient of 73–3% mobile phase A over the initial 11 min plus 4min
of re-equilibration to initial conditions was used. A flow rate gradient was also employed,
transitioning from 0.55 mL/min to 0.70 mL/min over the initial 11 min, and returning to 0.55
mL/min at 15 min. The method resulted in high extraction efficiency, accuracy, and precision.
However, successful implementation of this method for CVF required three major
modifications. First, an additional sample preparation was used prior to application to the SPE
columns. Pre-treatment with 1% perchloric acid followed by vortex and centrifugation was
used to precipitate proteins in the biological matrix and therefore decrease the amount of
endogenous interference. Notably, there was a limit to the amount of perchloric acid that could
be added. If the pH dropped too low, the lower limit of detection was affected due to minimal
drug extraction from the matrix. In addition, heating of CVF samples to inactivate HIV virus
was not performed because these samples were collected from HIV-uninfected subjects.
Second, a factor adjustment of detected peak area was used in the CVF method when 100 µL
of CVF could not be pipetted with a positive displacement pipettor (either due to the viscosity
of the matrix or because the subject was unable to collect 100 µL). For example, if only 40 µL
of CVF could be accurately pipetted, the resultant peak area was multiplied by 2.5 when
comparing the results to the standard curve. For plasma, a positive displacement pipettor is
unnecessary and a volume of 100 µL is easily obtained. Therefore, no adjustment of peak area
is necessary for plasma.
Third, the calibrators in the plasma method were made in undiluted plasma. However, a 1:3
dilution of CVF with normal saline was used to make these calibrators to allow homogenous
dispersion of standards and accurate pipetting. In contrast, the CVF samples collected from
subjects were not diluted or centrifuged. The CVF was pipetted directly from the cryovial to
the Eppendorf tube (except in the cases where the CVF could not be accurately pipetted, in
which the 1% perchloric acid and internal standard were added directly to the cryovial and the
entire CVF sample was rinsed out). The entire mixture in the Eppendorf tube (undiluted CVF
sample + perchloric acid + internal standard) was centrifuged, and that resulting supernatant
was applied to the SPE column. For most samples, only 40 µL of undiluted sample was pipetted
into the 1.5 mL Eppendorf tube, resulting in a similar amount of matrix compared to the
calibrator.
Minor modifications in the plasma method’s [6] mobile phase binary linear and flow rate
gradients did not adversely affect results. The retention times changed only by 0.2 min for
raltegravir and 0.1 min for IS. The adjusted gradients were also used for plasma samples from
the same pharmacokinetic study, and resulted in similar linearity, accuracy, and precision.
Although SVF was tested, unacceptable variability in the extraction of raltegravir precluded
its use for calibrators and quality controls. SVF was designed to mimic vaginal pH and
osmolarity [7], however there are several other components of vaginal fluid that are not
accounted for in SVF. Vaginal fluid is composed of vaginal transudite, exudate from
Bartholin’s and Skenes’s glands, exfoliated epithelial cells, residual urine, and fluids from the
upper reproductive tract such as cervical mucus and endometrial and tubal fluids [7].
This method is sensitive (as evidenced by a LLD of 0.05 mg/L) and specific (with minimal
endogenous interference). The method also meets the FDA’s recommendations for
bioanalytical method validation [10] accuracy (% deviation was within ±20% of the theoretical
value at the lower limit of quantification and within ±15% of the theoretical value for other
concentrations) and precision (%CV for the lower limit of quantification did not exceed 20%,
and did not exceed 15% for all other concentrations).
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Because of the sensitive, specific, accurate, and precise aspects of this method, it has been used
to analyze CVF samples from a clinical pharmacokinetic study [8]. The ability to detect
antiretroviral drugs in female genital tract secretions is essential for understanding
pharmacokinetic–pharmacodynamic investigations to inform clinical research in HIV
prevention. This method is assisting in this effort.
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(a) Blank chromatogram of extracted CVF illustrating minimal endogenous interference with
raltegravir (RAL) and internal standard (IS). (b) QC at 0.06 mg/L illustrating minimal
endogenous interference with raltegravir (RAL) and internal standard (IS). (c) Chromatogram
illustrating one CVF sample from pharmacokinetic study.
Talameh et al. Page 8














Mean (SE) concentration versus time pharmacokinetic profile in CVF and blood plasma on
day 7 for three healthy subjects given raltegravir 400 mg twice daily for 7 days.
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Table 2
Raltegravir extraction efficiency using various perchloric acid concentrations.
Concentration (mg/L) 0% perchloric acid (n = 3) 1% perchloric acid (n = 3) 2.5% perchloric acid (n = 3)
  .06 No peak 59% No peak
  .60 80% 58% 58%
6.0 82% 60% 61%
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